- Desfesoterodine
-
- $60.00 / 1mg
-
2025-12-05
- CAS:207679-81-0
- Min. Order:
- Purity: 99.77%
- Supply Ability: 10g
|
| | (R)-5-HydroxyMethyl Tolterodine Basic information |
| | (R)-5-HydroxyMethyl Tolterodine Chemical Properties |
| Melting point | 68-72°C | | Boiling point | 490.7±45.0 °C(Predicted) | | density | 1.060±0.06 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 9.61±0.48(Predicted) | | color | Off-White to Pale Yellow |
| | (R)-5-HydroxyMethyl Tolterodine Usage And Synthesis |
| Chemical Properties | Pale Yellow Solid | | Uses | (R)-5-HydroxyMethyl Tolterodine is a metabolite of Tolterodine (T535800), a muscarinic receptor antagonist used in the treatment of urinary incontinence. | | Uses | A metabolite of Tolterodine, a muscarinic receptor antagonist used in the treatment of urinary incontinence. | | Definition | ChEBI: Desfesoterodine is a diarylmethane. | | in vivo | Desfesoterodine (PNU-200577; 5-Hydroxymethyl Tolterodine; 0.1 and 1 mg/kg; IV) significantly increases bladder compliance after moderate and high doses[4].
In vivo, Desfesoterodine is significantly more potent at suppressing acetylcholine-induced urinary bladder contraction than electrically induced salivation in the anaesthetised cat (ID50=15 and 40 nmol/kg, respectively) [1].
| Animal Model: | Female Sprague Dawley rats at ages 9 to 11 weeks weighing 180 to 250 g[4] | | Dosage: | 0.1 and 1 mg/kg | | Administration: | IV; single imidafenacin administration | | Result: | Significantly increased bladder compliance after moderate and high doses.
|
|
| | (R)-5-HydroxyMethyl Tolterodine Preparation Products And Raw materials |
|